|Day's Range||77.76 - 78.46|
|52 Week Range||64.18 - 86.72|
|PE Ratio (TTM)||37.88|
|Dividend & Yield||2.08 (2.67%)|
|1y Target Est||N/A|
Radius Health, Inc. (RDUS) announced positive data from the ACTIVExtend study on Tymlos demonstrating significant reduction (84%) in the incidence of new vertebral fractures compared to placebo when dosed daily for 43 months.
Remicade, a top-selling drugs for the treatment of inflammatory disorders, is losing market share after the loss of exclusivity in European markets in February 2015.
AstraZeneca plc (AZN) announced top-line results from the EXSCEL study evaluating the cardiovascular (CV) safety profile of its type II diabetes drug Bydureon.